In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chair.
The compositions of the Board committees were decided to be as follows:
Personnel and Remuneration Committee:
Mikael Silvennoinen, Chair
Maziar Mike Doustdar
Veli-Matti Mattila
Hilpi Rautelin
Audit Committee:
Ari Lehtoranta, Chair
Kari Jussi Aho
Eija Ronkainen
Karen Lykke Sørensen
R&D Committee:
Hilpi Rautelin, Chair
Kari Jussi Aho
Veli-Matti Mattila
Eija Ronkainen
Karen Lykke Sørensen
The Company also has a Nomination Committee, the election of which was announced in a Stock Exchange Release on 29 April 2022. A change in the Nomination Committee composition was announced in a Stock Exchange Release on 21 March 2023.
All members of the Board of Directors have been evaluated to be independent of the company and its significant shareholders.
Orion Corporation
| Liisa Hurme President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Olli Huotari, Senior Vice President, Corporate Functions
Phone +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
